<code id='3AAEE5FAA6'></code><style id='3AAEE5FAA6'></style>
    • <acronym id='3AAEE5FAA6'></acronym>
      <center id='3AAEE5FAA6'><center id='3AAEE5FAA6'><tfoot id='3AAEE5FAA6'></tfoot></center><abbr id='3AAEE5FAA6'><dir id='3AAEE5FAA6'><tfoot id='3AAEE5FAA6'></tfoot><noframes id='3AAEE5FAA6'>

    • <optgroup id='3AAEE5FAA6'><strike id='3AAEE5FAA6'><sup id='3AAEE5FAA6'></sup></strike><code id='3AAEE5FAA6'></code></optgroup>
        1. <b id='3AAEE5FAA6'><label id='3AAEE5FAA6'><select id='3AAEE5FAA6'><dt id='3AAEE5FAA6'><span id='3AAEE5FAA6'></span></dt></select></label></b><u id='3AAEE5FAA6'></u>
          <i id='3AAEE5FAA6'><strike id='3AAEE5FAA6'><tt id='3AAEE5FAA6'><pre id='3AAEE5FAA6'></pre></tt></strike></i>

          explore

          explore

          author:leisure time    Page View:1697
          Adam's take main illustration
          Molly Ferguson/STAT

          Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down?

          Gline created $5 billion from $50 million — in less than one year.Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

          advertisement

          Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          6 phony surgeries that take placebo to the extreme
          6 phony surgeries that take placebo to the extreme

          AFP/GettyImagesMostofthetime,it’seasytobeintheplacebogroup ofaclinicaltrial:nosideeffects,minimalann

          read more
          Guidelines to prevent youth baseball injuries need more muscle
          Guidelines to prevent youth baseball injuries need more muscle

          Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

          read more

          Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo